January 24, 2023 10:37 AM EST

Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup

Amber Tong

When PolyPid revealed its lead program had flunked the main goal of the first Phase III trial, it underscored positive results from a subgroup analysis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Crushed by PhI­II an­tibi­ot­ic flop, PolyPid says it got FDA sup­port for a come­back — by fo­cus­ing on sub­group

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial